Biotech Values

[DewDiligence]

Correction to #msg-120426130:

Translation of the bolded sentence above: “We hope the FDA will listen to the advisory panel and approve CT-P13 for all five approved indications of branded Remicade (Crohn's disease, ulcerative colitis, RA, ankylosing spondylitis, psoriatic arthritis, and psoriasis), even through we conducted clinical trials in only two of those indications (RA and ankylosing spondylitis).”

Branded Remicade has six FDA-approved indications (not five)—the ones enumerated above.

How come nobody caught this? :- )